Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | Director | June 05, 2025 | June 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 43,651 |
Ending reported balance
After 2025-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-06-05 · Exercise / conversion · Acquired 50,000 · Balance 55,000 Row 2 · 2025-06-05 · Tax withholding · Disposed 11,349 · Balance 43,651 F1: Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on June 15, 2025. The reporting person received 38,651 shares of common stock on net exercise of an option to purchase 50,000 shares of common stock. The Company withheld 11,349 shares of common stock underlying the option as consideration for the exercise price, using the average of the high and low sales price on June 5, 2025 of $7.75, pursuant to the terms of the Company's 2007 Stock Option Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.76 · Expires 2025-06-15 | Direct | 0 |
Reported balance
After 2025-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-05 · Exercise / conversion · Disposed 50,000 · Balance 0 F2: The options vested in three equal annual installments beginning on June 15, 2016 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on June 15, 2025. The reporting person received 38,651 shares of common stock on net exercise of an option to purchase 50,000 shares of common stock. The Company withheld 11,349 shares of common stock underlying the option as consideration for the exercise price, using the average of the high and low sales price on June 5, 2025 of $7.75, pursuant to the terms of the Company's 2007 Stock Option Plan.
F2: The options vested in three equal annual installments beginning on June 15, 2016
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2025 Filed Jun 9, 2025 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001731122-25-000837 · ownership.xml · derivative · entry 3 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested in three equal annual installments beginning on June 15, 2016 Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Tax withholdingCommon stock | 11,349 | $7.75 | $87,954.75 |
DisclosureSEC source: 0001731122-25-000837 · ownership.xml · nonDerivative · entry 2 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,651 F1 · shares: Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on June 15, 2025. The reporting person received 38,651 shares of common stock on net exercise of an option to purchase 50,000 shares of common stock. The Company withheld 11,349 shares of common stock underlying the option as consideration for the exercise price, using the average of the high and low sales price on June 5, 2025 of $7.75, pursuant to the terms of the Company's 2007 Stock Option Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon stock | 50,000 | $1.76 | $88,000.00 |
DisclosureSEC source: 0001731122-25-000837 · ownership.xml · nonDerivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 01:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001731122-25-000515 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-03-31 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on March 31, 2026 Read SEC document |
| May 15, 2024 Filed May 17, 2024 10:01 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 5,000 | $4.52 | $22,600.00 |
DisclosureSEC source: 0001731122-24-000828 · ownership.xml · nonDerivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · price: Purchase price denominated in Euros has been translated to US dollars using an exchange rate of 0.92 Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 11:04 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001731122-24-000295 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-02-20 F1 · derivative.exercise_date: Options vest in equal installments over three years from the grant date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0001731122-23-000584 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-31 F1 · derivative.exercise_date: Options vest in equal instalments over three years from the grant date Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:14 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001731122-22-001147 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-27 Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:26 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001731122-21-001296 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-08-02 Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:28 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000014 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-30 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000022 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010441 · s113105_form4.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 21:18 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001615774-16-007384 · s104216_form4.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-09-22 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.